secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001437749-26-011546
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter
--------------------------------------------------------------------------------

- First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.
- Study plans to enroll ~215 participants across multiple sites; endpoints at 6 and 12 months.
- Prior feasibility study showed 96% procedural success at 12 months and 100% acute success.
- nPulse catheter uses nanosecond pulsed field ablation, integrated with Abbott EnSite X mapping.
- Company aims to evaluate safety and efficacy for drug-resistant paroxysmal AF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926011546/0001437749-26-011546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926011546/plse20260406_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-011546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer